Skip to main content
Top
Published in: Tumor Biology 5/2015

01-05-2015 | Research Article

Activation of FGF receptor signaling promotes invasion of non-small-cell lung cancer

Authors: Deping Zhao, Yi Lu, Chenlu Yang, Xiao Zhou, Zhifei Xu

Published in: Tumor Biology | Issue 5/2015

Login to get access

Abstract

The molecular regulation of metastasis of non-small-cell lung cancer (NSCLC) remains not completely defined. Here we showed significant higher MMP26 in the resected NSCLC than adjacent healthy tissue from the patients. Moreover, a strong correlation between MMP26 and the phosphorylated fibroblast growth factor receptor 1 (FGFR1) was detected. To examine the causal relationship between activated FGFR signaling and MMP26, we studied a human NSCLC cell line, A549. We found that FGF1-induced FGFR1 phosphorylation in A549 cells activated MMP26, resulting in an increase in cancer invasiveness. Inhibition of FGFR1 phosphorylation abolished FGF1-stimulated MMP26 activation, suggesting that activation of FGFR signaling pathway in NSCLC promotes cancer metastasis through MMP26. To define the signal transduction cascades downstream of FGFR1 activation for MMP26 activation, we used specific inhibitors for PI3K, ERK/MAPK, and JNK, respectively, to the FGF1-stimulated A549 cells. We found that only inhibition of JNK significantly decreased the activation of MMP26 in response to FGF1 stimulation, suggesting that activation of FGFR1 signaling may activate JNK to activate MMP26 in NSCLC. Our study thus highlights FGFR signaling pathway and MMP26 as novel therapeutic targets for NSCLC therapy.
Literature
1.
go back to reference Zarogoulidis K, Zarogoulidis P, Darwiche K, Boutsikou E, Machairiotis N, Tsakiridis K, et al. Treatment of non-small cell lung cancer (nsclc). J Thorac Dis. 2013;5:S389–96.PubMedPubMedCentral Zarogoulidis K, Zarogoulidis P, Darwiche K, Boutsikou E, Machairiotis N, Tsakiridis K, et al. Treatment of non-small cell lung cancer (nsclc). J Thorac Dis. 2013;5:S389–96.PubMedPubMedCentral
2.
go back to reference Mitsudomi T, Suda K, Yatabe Y. Surgery for nsclc in the era of personalized medicine. Nat Rev Clin Oncol. 2013;10:235–44.CrossRefPubMed Mitsudomi T, Suda K, Yatabe Y. Surgery for nsclc in the era of personalized medicine. Nat Rev Clin Oncol. 2013;10:235–44.CrossRefPubMed
3.
go back to reference Pallis AG, Syrigos KN. Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of nsclc. Lung Cancer. 2013;80:120–30.CrossRefPubMed Pallis AG, Syrigos KN. Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of nsclc. Lung Cancer. 2013;80:120–30.CrossRefPubMed
4.
go back to reference Jian H, Zhao Y, Liu B, Lu S. Sema4b inhibits mmp9 to prevent metastasis of non-small cell lung cancer. Tumour Biol. 2014;35:11051–6.CrossRefPubMed Jian H, Zhao Y, Liu B, Lu S. Sema4b inhibits mmp9 to prevent metastasis of non-small cell lung cancer. Tumour Biol. 2014;35:11051–6.CrossRefPubMed
5.
go back to reference Pei J, Lou Y, Zhong R, Han B. Mmp9 activation triggered by epidermal growth factor induced foxo1 nuclear exclusion in non-small cell lung cancer. Tumour Biol. 2014;35:6673–8.CrossRefPubMed Pei J, Lou Y, Zhong R, Han B. Mmp9 activation triggered by epidermal growth factor induced foxo1 nuclear exclusion in non-small cell lung cancer. Tumour Biol. 2014;35:6673–8.CrossRefPubMed
6.
go back to reference Takaishi H, Kimura T, Dalal S, Okada Y, D’Armiento J. Joint diseases and matrix metalloproteinases: a role for mmp-13. Curr Pharm Biotechnol. 2008;9:47–54.CrossRefPubMed Takaishi H, Kimura T, Dalal S, Okada Y, D’Armiento J. Joint diseases and matrix metalloproteinases: a role for mmp-13. Curr Pharm Biotechnol. 2008;9:47–54.CrossRefPubMed
7.
go back to reference Vincenti MP, Brinckerhoff CE. Transcriptional regulation of collagenase (mmp-1, mmp-13) genes in arthritis: integration of complex signaling pathways for the recruitment of gene-specific transcription factors. Arthritis Res. 2002;4:157–64.CrossRefPubMed Vincenti MP, Brinckerhoff CE. Transcriptional regulation of collagenase (mmp-1, mmp-13) genes in arthritis: integration of complex signaling pathways for the recruitment of gene-specific transcription factors. Arthritis Res. 2002;4:157–64.CrossRefPubMed
8.
go back to reference Balbin M, Pendas AM, Uria JA, Jimenez MG, Freije JP, Lopez-Otin C. Expression and regulation of collagenase-3 (mmp-13) in human malignant tumors. APMIS. 1999;107:45–53.CrossRefPubMed Balbin M, Pendas AM, Uria JA, Jimenez MG, Freije JP, Lopez-Otin C. Expression and regulation of collagenase-3 (mmp-13) in human malignant tumors. APMIS. 1999;107:45–53.CrossRefPubMed
9.
go back to reference Li D. Peaking of mmp-26 and timp-4 marks invasive transition in prostate cancer. Cell Res. 2006;16:741.CrossRefPubMed Li D. Peaking of mmp-26 and timp-4 marks invasive transition in prostate cancer. Cell Res. 2006;16:741.CrossRefPubMed
10.
go back to reference Yamamoto H, Vinitketkumnuen A, Adachi Y, Taniguchi H, Hirata T, Miyamoto N, et al. Association of matrilysin-2 (mmp-26) expression with tumor progression and activation of mmp-9 in esophageal squamous cell carcinoma. Carcinogenesis. 2004;25:2353–60.CrossRefPubMed Yamamoto H, Vinitketkumnuen A, Adachi Y, Taniguchi H, Hirata T, Miyamoto N, et al. Association of matrilysin-2 (mmp-26) expression with tumor progression and activation of mmp-9 in esophageal squamous cell carcinoma. Carcinogenesis. 2004;25:2353–60.CrossRefPubMed
11.
go back to reference Zhang Y, Zhao H, Wang Y, Lin Y, Tan Y, Fang X, et al. Non-small cell lung cancer invasion and metastasis promoted by mmp-26. Mol Med Rep. 2011;4:1201–9.PubMed Zhang Y, Zhao H, Wang Y, Lin Y, Tan Y, Fang X, et al. Non-small cell lung cancer invasion and metastasis promoted by mmp-26. Mol Med Rep. 2011;4:1201–9.PubMed
12.
go back to reference Li L, Mei TH, Zhou XD, Zhang XG. Expression and clinical significance of matrix metalloproteinase (mmp)-26 protein in non-small cell lung cancer. Ai Zheng. 2009;28:60–3.PubMed Li L, Mei TH, Zhou XD, Zhang XG. Expression and clinical significance of matrix metalloproteinase (mmp)-26 protein in non-small cell lung cancer. Ai Zheng. 2009;28:60–3.PubMed
13.
go back to reference Friesel R, Maciag T. Fibroblast growth factor prototype release and fibroblast growth factor receptor signaling. Thromb Haemost. 1999;82:748–54.PubMed Friesel R, Maciag T. Fibroblast growth factor prototype release and fibroblast growth factor receptor signaling. Thromb Haemost. 1999;82:748–54.PubMed
14.
go back to reference Jaye M, Schlessinger J, Dionne CA. Fibroblast growth factor receptor tyrosine kinases: molecular analysis and signal transduction. Biochim Biophys Acta. 1992;1135:185–99.CrossRefPubMed Jaye M, Schlessinger J, Dionne CA. Fibroblast growth factor receptor tyrosine kinases: molecular analysis and signal transduction. Biochim Biophys Acta. 1992;1135:185–99.CrossRefPubMed
15.
go back to reference Fujimoto J, Hori M, Ichigo S, Tamaya T. Expressions of the fibroblast growth factor family (fgf-1, −2 and −4) mrna in endometrial cancers. Tumour Biol. 1996;17:226–33.CrossRefPubMed Fujimoto J, Hori M, Ichigo S, Tamaya T. Expressions of the fibroblast growth factor family (fgf-1, −2 and −4) mrna in endometrial cancers. Tumour Biol. 1996;17:226–33.CrossRefPubMed
16.
go back to reference Soundararajan P, Fawcett JP, Rafuse VF. Guidance of postural motoneurons requires mapk/erk signaling downstream of fibroblast growth factor receptor 1. J Neurosci. 2010;30:6595–606.CrossRefPubMed Soundararajan P, Fawcett JP, Rafuse VF. Guidance of postural motoneurons requires mapk/erk signaling downstream of fibroblast growth factor receptor 1. J Neurosci. 2010;30:6595–606.CrossRefPubMed
17.
go back to reference Kuslak SL, Marker PC. Fibroblast growth factor receptor signaling through mek-erk is required for prostate bud induction. Differentiation. 2007;75:638–51.CrossRefPubMed Kuslak SL, Marker PC. Fibroblast growth factor receptor signaling through mek-erk is required for prostate bud induction. Differentiation. 2007;75:638–51.CrossRefPubMed
18.
go back to reference Williamson AJ, Dibling BC, Boyne JR, Selby P, Burchill SA. Basic fibroblast growth factor-induced cell death is effected through sustained activation of p38mapk and up-regulation of the death receptor p75ntr. J Biol Chem. 2004;279:47912–28.CrossRefPubMed Williamson AJ, Dibling BC, Boyne JR, Selby P, Burchill SA. Basic fibroblast growth factor-induced cell death is effected through sustained activation of p38mapk and up-regulation of the death receptor p75ntr. J Biol Chem. 2004;279:47912–28.CrossRefPubMed
19.
go back to reference Kan M, Wu X, Wang F, McKeehan WL. Specificity for fibroblast growth factors determined by heparan sulfate in a binary complex with the receptor kinase. J Biol Chem. 1999;274:15947–52.CrossRefPubMed Kan M, Wu X, Wang F, McKeehan WL. Specificity for fibroblast growth factors determined by heparan sulfate in a binary complex with the receptor kinase. J Biol Chem. 1999;274:15947–52.CrossRefPubMed
20.
go back to reference Dienstmann R, Rodon J, Prat A, Perez-Garcia J, Adamo B, Felip E, et al. Genomic aberrations in the fgfr pathway: Opportunities for targeted therapies in solid tumors. Ann Oncol. 2014;25:552–63.CrossRefPubMed Dienstmann R, Rodon J, Prat A, Perez-Garcia J, Adamo B, Felip E, et al. Genomic aberrations in the fgfr pathway: Opportunities for targeted therapies in solid tumors. Ann Oncol. 2014;25:552–63.CrossRefPubMed
21.
go back to reference Parker BC, Engels M, Annala M, Zhang W. Emergence of fgfr family gene fusions as therapeutic targets in a wide spectrum of solid tumours. J Pathol. 2014;232:4–15.CrossRefPubMed Parker BC, Engels M, Annala M, Zhang W. Emergence of fgfr family gene fusions as therapeutic targets in a wide spectrum of solid tumours. J Pathol. 2014;232:4–15.CrossRefPubMed
22.
go back to reference Wu YM, Su F, Kalyana-Sundaram S, Khazanov N, Ateeq B, Cao X, et al. Identification of targetable fgfr gene fusions in diverse cancers. Cancer Discov. 2013;3:636–47.CrossRefPubMedPubMedCentral Wu YM, Su F, Kalyana-Sundaram S, Khazanov N, Ateeq B, Cao X, et al. Identification of targetable fgfr gene fusions in diverse cancers. Cancer Discov. 2013;3:636–47.CrossRefPubMedPubMedCentral
23.
go back to reference Beau-Faller M, Gaub MP, Schneider A, Guerin E, Meyer N, Ducrocq X, et al. Allelic imbalance at loci containing fgfr, fgf, c-met and hgf candidate genes in non-small cell lung cancer sub-types, implication for progression. Eur J Cancer. 2003;39:2538–47.CrossRefPubMed Beau-Faller M, Gaub MP, Schneider A, Guerin E, Meyer N, Ducrocq X, et al. Allelic imbalance at loci containing fgfr, fgf, c-met and hgf candidate genes in non-small cell lung cancer sub-types, implication for progression. Eur J Cancer. 2003;39:2538–47.CrossRefPubMed
24.
go back to reference Ren M, Hong M, Liu G, Wang H, Patel V, Biddinger P, et al. Novel fgfr inhibitor ponatinib suppresses the growth of non-small cell lung cancer cells overexpressing fgfr1. Oncol Rep. 2013;29:2181–90.PubMed Ren M, Hong M, Liu G, Wang H, Patel V, Biddinger P, et al. Novel fgfr inhibitor ponatinib suppresses the growth of non-small cell lung cancer cells overexpressing fgfr1. Oncol Rep. 2013;29:2181–90.PubMed
25.
go back to reference Volm M, Koomagi R, Mattern J, Stammler G. Prognostic value of basic fibroblast growth factor and its receptor (fgfr-1) in patients with non-small cell lung carcinomas. Eur J Cancer. 1997;33:691–3.CrossRefPubMed Volm M, Koomagi R, Mattern J, Stammler G. Prognostic value of basic fibroblast growth factor and its receptor (fgfr-1) in patients with non-small cell lung carcinomas. Eur J Cancer. 1997;33:691–3.CrossRefPubMed
26.
go back to reference Lieber M, Smith B, Szakal A, Nelson-Rees W, Todaro G. A continuous tumor-cell line from a human lung carcinoma with properties of type ii alveolar epithelial cells. Int J Cancer. 1976;17:62–70.CrossRefPubMed Lieber M, Smith B, Szakal A, Nelson-Rees W, Todaro G. A continuous tumor-cell line from a human lung carcinoma with properties of type ii alveolar epithelial cells. Int J Cancer. 1976;17:62–70.CrossRefPubMed
27.
go back to reference Kang M, Choi S, Jeong SJ, Lee SA, Kwak TK, Kim H, et al. Cross-talk between tgfbeta1 and egfr signalling pathways induces tm4sf5 expression and epithelial-mesenchymal transition. Biochem J. 2012;443:691–700.CrossRefPubMed Kang M, Choi S, Jeong SJ, Lee SA, Kwak TK, Kim H, et al. Cross-talk between tgfbeta1 and egfr signalling pathways induces tm4sf5 expression and epithelial-mesenchymal transition. Biochem J. 2012;443:691–700.CrossRefPubMed
28.
go back to reference Xiao X, Gaffar I, Guo P, Wiersch J, Fischbach S, Peirish L, et al. M2 macrophages promote beta-cell proliferation by up-regulation of smad7. Proc Natl Acad Sci U S A. 2014;111:E1211–20.CrossRefPubMedPubMedCentral Xiao X, Gaffar I, Guo P, Wiersch J, Fischbach S, Peirish L, et al. M2 macrophages promote beta-cell proliferation by up-regulation of smad7. Proc Natl Acad Sci U S A. 2014;111:E1211–20.CrossRefPubMedPubMedCentral
29.
go back to reference Xu Y, Xia W, Baker D, Zhou J, Cha HC, Voorhees JJ, et al. Receptor-type protein tyrosine phosphatase beta (rptp-beta) directly dephosphorylates and regulates hepatocyte growth factor receptor (hgfr/met) function. J Biol Chem. 2011;286:15980–8.CrossRefPubMedPubMedCentral Xu Y, Xia W, Baker D, Zhou J, Cha HC, Voorhees JJ, et al. Receptor-type protein tyrosine phosphatase beta (rptp-beta) directly dephosphorylates and regulates hepatocyte growth factor receptor (hgfr/met) function. J Biol Chem. 2011;286:15980–8.CrossRefPubMedPubMedCentral
Metadata
Title
Activation of FGF receptor signaling promotes invasion of non-small-cell lung cancer
Authors
Deping Zhao
Yi Lu
Chenlu Yang
Xiao Zhou
Zhifei Xu
Publication date
01-05-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 5/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-3001-y

Other articles of this Issue 5/2015

Tumor Biology 5/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine